Comprehensive Insight Generation for Product Development
Target RWE generates complete, longitudinal datasets with the power of advanced analytics and rigorous causal inference methodologies to uncover deep insights on unmet needs, disease progression, and the efficacy and safety of new treatments in the real world.
Schedule a MeetingA Partner for Your Clinical Programs
With strong expertise in liver disease, gastroenterology, and dermatology, Target RWE’s multi-stakeholder model allows you to develop robust disease protocols to inform study objectives and endpoints. Our registries contain all relevant disease state variables, which when combined with our digital collection of patient and clinician reported outcomes and biosamples provide a framework for decisions on study entry criteria and site selection – reducing unnecessary procedures and costly protocol amendments.
Demonstrate Valuable Insights with
Real-World Evidence
Target RWE’s cross-sectional and longitudinally complete registries encompass diverse patient populations beyond those traditionally captured in Phase 2 and 3 trials, generating more meaningful evidence on product effectiveness and safety in the real world. We provide insights on natural history of disease, treatment patterns, disease progression and other clinical questions. Execute your publication strategy with confidence and speed by joining our unique collaborative academic model, which taps not just into our patient registries but our network of leading clinical investigators.
Comprehensive Treatment Comparisons for Informed Decision Making
Leverage our proven advanced analytics and diverse real-world data to evaluate comparative effectiveness, safety, and cost-effectiveness of new therapies. Target RWE’s patient-centered analyses utilize patient-reported outcome (PRO) and clinician-reported outcome (ClinRO) measures to inform disease burden, empowering you with the insights necessary to improve healthcare utilization.
Real-World Data for Regulatory Compliance & Safety
Target RWE’s fit-for-purpose longitudinal registries, ability to incorporate clinician-reported outcomes, and validated analytics software provide comprehensive solutions to meet FDA and pharmacovigilance risk assessment committee requests for new drug applications. Our research collaboration agreement with the FDA, combined with proven experience in meeting post marketing commitments and managing adjudication committees, enable us to be your trusted partner for regulatory decision-making.
Patient Insights for Strategic Product Positioning
Target RWE's detailed patient journeys identify meaningful data points in disease that can inform your product positioning and marketing plan. Our large datasets, combined with novel analytical and causal inference methodology identify patient phenotypes with high unmet need, predict disease progression, and support identification of patients who will benefit most from your new therapy.
Fit-for-Purpose Registries for Advanced Research
Target RWE collaborates with a renowned network of clinical investigators to enroll large patient cohorts, capturing up to 5 years of retrospective and 15 years of prospective follow-up – creating some of the largest and most comprehensive real-world patient registries in the U.S.
Therapeutic Area-Relevant Curation for Comprehensive Insights
Target RWE's data curation engine processes complex data using therapeutic area-relevant deterministic rules and machine learning models trained by clinical experts.
Our secure proprietary technology and well-trained natural language processing models curate data from clinician notes, patient-reported outcomes, and other sources to build complete and accurate patient journeys.
Explore our Data Curation Engine
Advanced Causal Inference Analytics
Target RWE's team conducts data-agnostic analyses rooted in modern epidemiological methods and cutting-edge statistical principles. Our proprietary causalRisk™ software offers validated analytics and causal inference methodologies that address complications in real-world data, handling informative censoring, time-varying treatments, or time-varying covariates.
Explore causalRisk™
Powerful Visualizations to Bring Research to Life
Tap into causalPHR™, our interactive and collaborative data visualization software, to explore disease progression and stratify by patient subpopulations of interest. causalPHR™ brings your real world analyses to life, making visualizing, stratifying, and filtering analytical results straightforward and intuitive.
Explore causalPHR™New Publications
Dermatology
Healthcare Disparities in Hidradenitis Suppurativa in the US: TARGET-DERM HS
Dermatology
Characterization of patient perception of odor severity in hidradenitis suppurativa using TARGET-DERM HS
Dermatology
Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry.
Hepatocellular Carcinoma (HCC)
Real-World Treatment Patterns Among US Adults with Enresectable Hepatocellular Carcinoma (HCC) Eligible For Locoregional Therapy (LRT)
Dermatology
Correlation between achieving SALT 20 score and clinician- and patient-reported outcomes among patients diagnosed with alopecia areata in the US: An assessment from the TARGET-DERM AA registry.
Hepatocellular Carcinoma (HCC)
DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy
In the News
How does causalStudio™ address the key regulatory requirements for data integrity, traceability, and analysis?
An Overview of MASH: Advancements in Diagnosis, Treatment, and the Role of Real-World Data
Addressing the Burden of Hidradenitis Suppurativa: The Often-Hidden Impact on Quality of Life
AASLD Opens Call for Applications for Sites to Participate in TARGET-LD and the Cirrhosis Quality Collaborative (CQC Data Registry)
Have a Question or Want to Learn More?
By Submitting this form, you consent to your information used by Target RWE for the purpose of contacting you to better understand your potential interest in Target RWE and/or its services. For more information, see our privacy policy.